Unlike in CML where treatment-free remission is an established goal, discontinuing interferon in PV after a deep molecular response is considered theoretical and experimental. Clinicians caution against setting this as an expectation for patients, as most will require indefinite therapy to maintain control.

While the new CML drug Asciminib demonstrates better efficacy, its most significant advantage is superior tolerability. Clinical trial data shows it causes significantly fewer treatment discontinuations due to adverse events compared to both Imatinib and second-generation TKIs, improving patient adherence and quality of life.

Interferon therapy is being evaluated in a distinct niche from JAK inhibitors. It is targeted at patients with early or low-risk myelofibrosis, not for immediate symptom control, but with the strategic goal of potentially modifying the disease course and slowing its natural progression.

Despite label recommendations for rapid dose escalation of ropeginterferon, experienced clinicians advocate for a slower, more patient-centric approach. This prioritizes long-term tolerability and adherence, which is crucial for achieving disease modification, over achieving rapid hematologic control.

The primary goal in Chronic Myeloid Leukemia (CML) has evolved from survival to tolerability and treatment-free remission. These goals are not uniform; younger patients prioritize stopping treatment to start families, while long-term patients increasingly value better tolerability over marginal efficacy gains.

While tyrosine kinase inhibitors (TKIs) reduced overall CML transplants, a dangerous trend has emerged. Clinicians are waiting too long to transplant high-risk patients, often until after they reach an advanced disease state, which significantly worsens outcomes compared to an early transplant in the chronic phase.

Long-term CML therapy success hinges on adherence. Minor intolerances and lifestyle inconveniences, which accumulate over a lifetime of treatment, are more likely to cause patients to stop therapy than the drug failing to work, compromising outcomes.

Recent non-inferiority trials affirm that fixed-duration combination therapies are viable alternatives to continuous BTK inhibitors. However, clinicians must look beyond the headline conclusion, as numerical data can show slightly worse progression-free survival for high-risk subgroups within the acceptable non-inferiority margin, complicating treatment decisions.

Proactively, some hematologists now offer interferon-based therapy to very young, asymptomatic low-risk PV patients. The rationale is to leverage the drug's potential for disease modification by reducing JAK2 allele burden early on, even though this is not yet a formal guideline-supported indication.